Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1016/j.vaccine.2005.01.081
Title (Primary) Tumour-dentritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
Author Trefzer, U.; Herberth, G. ORCID logo ; Wohlan, K.; Milling, A.; Thiemann, M.; Sharav, T.; Sparbier, K.; Sterry, W.; Walden, P.
Source Titel Vaccine
Year 2005
Department IMMU
Volume 23
Issue 17-18
Page From 2367
Page To 2373
Language englisch
Keywords Tumour vaccine; Melanoma; T cell; Immune monitoring; Immune escape; Clinical trial
Abstract Hybrid cell vaccines of autologous tumour cells fused with allogenic dendritic cells (DC) combine the tumour's antigenicity with the immune-stimulatory capacity of mature dendritic cells and allogenic MHC class II molecules to activate T cell help and induce tumour-specific cytotoxic T cells. This concept was tested in a clinical trial with melanoma stage III and IV patients. Seventeen patients were evaluated: one experienced complete, one partial response and six stable disease with long survival times. Eleven of fourteen patients, clinical responders and non-responders alike, mounted high-frequency T cell responses to various tumour-associated antigens. Failing clinical responses correlated with loss of antigenicity.
Persistent UFZ Identifier https://www.ufz.de/index.php?en=20939&ufzPublicationIdentifier=3846
Trefzer, U., Herberth, G., Wohlan, K., Milling, A., Thiemann, M., Sharav, T., Sparbier, K., Sterry, W., Walden, P. (2005):
Tumour-dentritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
Vaccine 23 (17-18), 2367 - 2373 10.1016/j.vaccine.2005.01.081